GlobalData on MSN19h
Inceptor Bio doses first subject in trial of IB-T101 for renal cell carcinoma
US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...
Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 Financing
Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...
pharmaphorum1d
Pfizer's Arena buyout looks canny, as etrasimod aces phase 3 trials
Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...